Tumor-targeting mAb are widely used in the treatment of a variety of solid and hematopoietic tumors and represent the first immunotherapeutic approach successfully arrived to the clinic. Nevertheless, the role of distinct immune mechanisms in contributing to their therapeutic efficacy is not completely understood and may vary depending on tumor- or antigen/antibody-dependent characteristics. Availability of next-generation, engineered, tumor-targeting mAb, optimized in their capability to recruit selected immune effectors, re-enforces the need for a deeper understanding of the mechanisms underlying anti-tumor mAb functionality. NK cells participate with a major role to innate anti-tumor responses, by exerting cytotoxic activity and producing a vast array of cytokines. As the CD16 (low-affinity FcγRIIIA)-activating receptor is expressed on the majority of NK cells, its effector functions can be ideally recruited against therapeutic mAb-opsonized tumor cells. The exact role of NK cells in determining therapeutic efficacy of tumor-targeting mAb is still unclear and much sought after. This knowledge will be instrumental to design innovative combination schemes with newly validated immunomodulatory agents. We will summarize what is known about the role of NK cells in therapeutic anti-tumor mAb therapy, with particular emphasis on RTX chimeric anti-CD20 mAb, the first one used in clinical practice for treating B cell malignancies.

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions / Battella, Simone; Cox, Maria Christina; Santoni, Angela; Palmieri, Gabriella. - In: JOURNAL OF LEUKOCYTE BIOLOGY. - ISSN 0741-5400. - STAMPA. - 1:99(2016), pp. 87-96. [10.1189/jlb.5VMR0415-141R]

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions

BATTELLA, SIMONE;SANTONI, Angela;PALMIERI, Gabriella
2016

Abstract

Tumor-targeting mAb are widely used in the treatment of a variety of solid and hematopoietic tumors and represent the first immunotherapeutic approach successfully arrived to the clinic. Nevertheless, the role of distinct immune mechanisms in contributing to their therapeutic efficacy is not completely understood and may vary depending on tumor- or antigen/antibody-dependent characteristics. Availability of next-generation, engineered, tumor-targeting mAb, optimized in their capability to recruit selected immune effectors, re-enforces the need for a deeper understanding of the mechanisms underlying anti-tumor mAb functionality. NK cells participate with a major role to innate anti-tumor responses, by exerting cytotoxic activity and producing a vast array of cytokines. As the CD16 (low-affinity FcγRIIIA)-activating receptor is expressed on the majority of NK cells, its effector functions can be ideally recruited against therapeutic mAb-opsonized tumor cells. The exact role of NK cells in determining therapeutic efficacy of tumor-targeting mAb is still unclear and much sought after. This knowledge will be instrumental to design innovative combination schemes with newly validated immunomodulatory agents. We will summarize what is known about the role of NK cells in therapeutic anti-tumor mAb therapy, with particular emphasis on RTX chimeric anti-CD20 mAb, the first one used in clinical practice for treating B cell malignancies.
2016
ADCC; FcγRs; chemoimmunotherapy; rituximab
01 Pubblicazione su rivista::01a Articolo in rivista
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions / Battella, Simone; Cox, Maria Christina; Santoni, Angela; Palmieri, Gabriella. - In: JOURNAL OF LEUKOCYTE BIOLOGY. - ISSN 0741-5400. - STAMPA. - 1:99(2016), pp. 87-96. [10.1189/jlb.5VMR0415-141R]
File allegati a questo prodotto
File Dimensione Formato  
Battella_Natural-killer_2016.pdf

solo gestori archivio

Note: articolo principale
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 643.59 kB
Formato Adobe PDF
643.59 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/797448
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 52
social impact